A new approach to treatment of hematological malignancies. A GAB1 inhibitor for use in a method of treatment of a hematological malignancy is disclosed. The GAB1 inhibitor may be administered alone, or simultaneously or sequentially with a BTK inhibitor to achieve a synergistic effect.

A new approach to treatment of hematological malignancies. A GAB1 inhibitor for use in a method of treatment of a hematological malignancy is disclosed. The GAB1 inhibitor may be administered alone, or simultaneously or sequentially with a BTK inhibitor to achieve a synergistic effect.

Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.

Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof.

The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof.

##STR00001##

wherein the symbols in the formula are defined below:
R.sup.1: e.g., a C1-C6 alkyl group; R.sup.2: a C1-C6 alkyl group;
A: e.g., an oxygen atom; and R.sup.3: e.g., a C1-C6 alkyl group.

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof.

The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof.

##STR00001##

wherein the symbols in the formula are defined below:
R.sup.1: e.g., a C1-C6 alkyl group; R.sup.2: a C1-C6 alkyl group;
A: e.g., an oxygen atom; and R.sup.3: e.g., a C1-C6 alkyl group.

The present invention relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of age-related diseases by administering a compound of Formula 1 to a subject in need thereof. The invention further relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of premature aging disorders by administering a compound of Formula 1 to a subject in need thereof.

The present invention relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of age-related diseases by administering a compound of Formula 1 to a subject in need thereof. The invention further relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of premature aging disorders by administering a compound of Formula 1 to a subject in need thereof.

The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.